Varenicline for tobacco dependence: Panacea or plight?

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 11, 2011, Pages 1799-1812

  Williams, Jill M ^a,b   Steinberg, Michael B ^a,b   Steinberg, Marc L ^a,b   Gandhi, Kunal K ^a,b   Ulpe, Rajiv ^c   Foulds, Jonathan ^d  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Pharmacotherapy; Smoking; Smoking cessation; Tobacco; Varenicline

Indexed keywords

AMFEBUTAMONE; ATENOLOL; CLONAZEPAM; DIPHENHYDRAMINE; DULOXETINE; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LORAZEPAM; METOPROLOL; MODAFINIL; MONTELUKAST; NICOTINIC ACID; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PANTOPRAZOLE; PRAMIPEXOLE; PRAZOSIN; QUETIAPINE; SERTRALINE; SPIRONOLACTONE; TERAZOSIN; TIOTIXENE; TOPIRAMATE; TRIFLUOPERAZINE; VALPROIC ACID; VARENICLINE;

AGITATION; ASIAN; BEHAVIOR CHANGE; BIPOLAR DISORDER; BORDERLINE STATE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; DREAMING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HARM REDUCTION; HUMAN; INSOMNIA; MOOD CHANGE; NAUSEA; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; POSTTRAUMATIC STRESS DISORDER; REVIEW; REWARD; SCHIZOPHRENIA; SIDE EFFECT; SMOKELESS TOBACCO; SMOKING CESSATION; SUBSTANCE ABUSE; SUICIDAL IDEATION; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; BENZAZEPINES; HUMANS; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION; TOBACCO USE CESSATION; TOBACCO USE DISORDER; TOBACCO, SMOKELESS;

EID: 79960272736     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.587121     Document Type: Review

References (82)

1. Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 2006;166:1553-9
2. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7 (Pubitemid 40664098)
3. Kuehn BM. FDA speeds smoking cessation drug review. JAMA 2006;295:614 (Pubitemid 43209052)
4. Fontanarosa PB, DeAngelis CD. Update on JAMA-EXPRESS Rapid Review and Publication. JAMA 2008;300:2920-1
5. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA 2006;296:47-55
6. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. A randomized controlled trial. JAMA 2006;296:56-63
7. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71
8. Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 2006;34:121-30 (Pubitemid 43042653)
9. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008;179:135-44 (Pubitemid 352020119)
10. Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006;6:300
11. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011;16.
12. Ravva P, Gastonguay MR, French JL, et al. Quantitative assessment of exposure response relationships for the efficacy and tolerability of varenicline for smoking cessation. Clin Pharmacol Ther 2010;87:336-44
13. Hughes JR, Keely JP, Niaura RS, et al. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003;5:13-25 (Pubitemid 36285465)
14. Dervaux A, Kanit M, Laqueille X. Efficacy of varenicline for smoking cessation. JAMA 2006;296:2555; author reply 2555-6
15. Lasser KE, Boyd JW. Varenicline and smokers with mental illnesses. Lancet 2008;372:1218-19
16. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA 2000;284:2606-10
17. Hagman BT, Delnevo CD, Hrywna M, Williams JM. Tobacco use among those with serious psychological distress: findings from the National Survey of Drug Use and Health, 2002. Addict Behav 2008;33:582-92
18. Han ES, Foulds J, Steinberg MB, et al. Characteristics and smoking cessation outcomes of patients returning for repeat tobacco dependence treatment. Int J Clin Pract 2006;60:1068-74 (Pubitemid 44226744)
19. Piper ME, Smith SS, Schlam TR, et al. Psychiatric disorders in smokers seeking treatment for tobacco dependence: relations with tobacco dependence and cessation. J Consult Clin Psychol 2010;78:13-23
20. McClure JB, Swan GE, Catz SL, et al. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat 2010;38:394-402
21. Clarke DE, Eaton WW, Petronis KR, et al. Increased risk of suicidal ideation in smokers and former smokers compared to never smokers: evidence from the baltimore ECA follow-up study. Suicide Life Threat Behav 2010;40:307-18
22. Breslau N, Schultz LR, Johnson EO, et al. Smoking and the risk of suicidal behavior: a prospective study of a community sample. Arch Gen Psychiatry 2005;62:328-34 (Pubitemid 40990978)
23. Ostacher MJ, Nierenberg AA, Perlis RH, et al. The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. J Clin Psychiatry 2006;67:1907-11 (Pubitemid 46048187)
24. Oquendo MA, Bongiovi-Garcia ME, Galfalvy H, et al. Sex differences in clinical predictors of suicidal acts after major depression: a prospective study. Am J Psychiatry 2007;164:134-41 (Pubitemid 46154792)
25. Moriya F, Hashimoto Y, Furumiya J. Nicotine and cotinine levels in body fluids of smokers who committed suicide. Forensic Sci Int 2007;168(2-3):102-5 (Pubitemid 46617842)
26. Berlin I, Henian C, Covey LS. Depressive mood, suicide ideation and anxiety in smokers who do and smokers who do not manage to stop smoking after a target quit day. Addiction 2010;105:2209-16
27. Kuehn BM. Studies linking smoking-cessation drug with suicide risk spark concerns. JAMA 2009;301:1007-8
28. US Food and Drug Administration. Drug Safety and Availability; Available from: www.fda.gov/ Drugs/Drugsafety [Last accessed 1 March 2011]
29. Moore TJ, Glenmullen J, Furberg CD. Thoughts and acts of aggression/violence toward others reported in association with varenicline. Ann Pharmacother 2010;44:1389-94
30. Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry 2008;165:774 (Pubitemid 351810551)
31. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007;164:1269
32. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007;164:1269-70 (Pubitemid 47292424)
33. Kutscher EC, Stanley M, Oehlke K. Chantix-induced mental status changes in a young healthy female. S D Med 2009;62:193-195
34. DiPaula BA, Thomas MD. Worsening psychosis induced by varenicline in a hospitalized psychiatric patient. Pharmacotherapy 2009;29:852-7
35. Lyon GJ. Possible varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline personality disorder, and methamphetamine abuse in remission. J Clin Psychopharmacol 2008;28:720-1
36. Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008;13:511-14 (Pubitemid 351960775)
37. Raidoo BM, Kutscher EC. Visual hallucinations associated with varenicline: a case report. J Med Case Reports 2009;3:7560
38. Ismail Z, Syms J, Blumberger D, George TP. Varenicline induced polydipsia and hyponatremia in a patient with schizophrenia. Schizophr Res 2010;119:268
39. Morstad AE, Kutscher EC, Kennedy WK, Carnahan RM. Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother 2008;42:288-9 (Pubitemid 351238580)
40. Pirmoradi P, Roshan S, Nadeem SS. Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. Am J Health Syst Pharm 2008;65:1624-6
41. Bird ML, Vesta KS. Varenicline-associated acute renal failure. Ann Pharmacother 2008;42:1908-11
42. Duparc A, Gosset P, Caron J, et al. Acute generalized exanthematous pustulosis caused by varenicline. J Eur Acad Dermatol Venereol 2009;23:1111-12
43. Kristensen PL, Pedersen-Bjergaard U, Thorsteinsson B. Varenicline may trigger severe hypoglycaemia in type 1 diabetes. Diabet Med 2008;25:625-6 (Pubitemid 351590883)
44. Smith RC, Lindenmayer JP, Davis JM, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009;110:149-55
45. Fatemi SH. Varenicline efficacy and tolerability in a subject with schizophrenia. Schizophr Res 2008;103:328-9
46. Evins AE, Goff DC. Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry 2008;69:1016 (Pubitemid 351944959)
47. Anghelescu I. Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient. J Neuropsychiatry Clin Neurosci 2009;21:102-3
48. Weiner E, Buchholz A, Coffay A, et al. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res 2011;129(1):94-5
49. McClure JB, Swan GE, Jack L, et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med 2009;24:563-9
50. Philip NS, Carpenter LL, Tyrka AR, et al. Varenicline augmentation in depresses smokers: an 8-week, open-label study. J Clin Psychiatry 2009;70:1026-31
51. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008;103:146-54. (Pubitemid 350233424)
52. Purvis TL, Mambourg SE, Balvanz TM, et al. Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. Ann Pharmacother 2009;43:862-7
53. Poling J, Rounsaville B, Gonsai K, et al. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am J Addict 2010;19:401-8
54. Steinberg MB, Bover MT, Richardson DL, et al. Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies. Drug Alcohol Depend 2011;114:77-81
55. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805.
56. Tonstad S, Davies S, Flammer M, et al. Psychiatric adverse events in randomized double-blind, placebo-controleld clinical trials of varenicline. A pooled analysis. Drug Saf 2010;33:289-301.
57. Garza D, Murphy M, Tseng LJ, et al. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biol Psychiatry 2011;69(11):1075-82
58. Stapleton J. Do the 10 UK suicides among those taking the smoking cessation drug varenicline suggest a causal link? Addiction 2009;104:864-5
59. Henningfield JE, Shiffman S, Ferguson SG, Gritz ER. Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther 2009;123:1-16
60. Spiller K, Xi Z-X, Li X, et al. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of a4b2 nicotinic receptors in rats. Neuropharmacology 2009;57:60-6
61. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the a4b2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007;52:985-94 (Pubitemid 46227486)
62. McColl SL, Burstein AH, Reeves KR, et al. Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. Clin Pharmacol Ther 2008;83:607-14 (Pubitemid 351417072)
63. Perkins KA, Mercincavage M, Fonte CA, et al. Vareniclines effects on acute smoking behavior and reward and their association with subsequent abstinence. Psychopharmacology 2010;210:45-51
64. McKee SA, Harrison ELR, OMalley SS, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry 2009;66:185-90
65. Patterson F, Jepson C, Strasser AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 2009;65:144-49
66. Sofuoglu M, Herman AI, Mooney M, Waters AJ. Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology 2009;207:153-62
67. Ebbert JO, Croghan IT, North F, Schroeder DR. A pilot study to assess smokeless tobacco use reduction with varenicline. Nicotine Tob Res 2010;12:1037-40
68. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 2008;197:371-7
69. Williams KE, Reeves KR, Billing CB Jr, et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23:793-801 (Pubitemid 46646499)
70. Russ C, Rennard S, Arteaga C, Hughes J. Is setting a quit date a priori essential? A comparison of studies of varenicline using flexible vs. a priori quit date protocols. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT) 17th Annual Meeting, 16 - 19 February 2011, Westin Harbour Castle, Toronto, Canada
71. Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008;24:1931-41
72. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008;63:717-24
73. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service, 2008.
74. Issa JS, Ogawa TM, Soares de Moura AS, Pereira AC. Effectiveness of varenicline combination therapy in real life setting: PAF database study. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT) 17th Annual Meeting, 16 - 19 February 2011, Westin Harbour Castle, Toronto, Canada.
75. Ebbert JO, Burke MV, Hays JT, Hurt RD. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009;11:572-6
76. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010;121:221-9.
77. Willers S. Smoking cessation treatment using varenicline in a patient population with mostly heart and lung diseases. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, 16 - 19 February 2011, Westin Harbour Castle, Toronto, Canada.
78. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in mild-to-moderate COPD: a randomized controlled trial. Chest 2011;139(3):591-9
79. Steinberg MB, Randall J, Greenhaus S, et al. Tobacco dependence treatment intervention for hospitalized smokers: a pilot randomized, controlled trial. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, 16 - 19 February 2011, Westin Harbour Castle, Toronto, Canada.
80. Xiao Y, Lv Y, Zhang X, et al. The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers. Int J Clin Pharmacol Ther 2009;47:246-54
81. Baha MY, Le Faou AL. Smoking cessation interventions offered to French adult light smokers: a heterogeneous population with specific needs. Eur Addict Res 2010;16:162-9
82. Fagerstrom K, Gilljam H, Metcalfe M, et al. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ 2010;341:c6549